VitaNova Life Sciences Corporation (YJGJD) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Mar 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YJGJD SEC filings page.
VitaNova Life Sciences Corporation (YJGJD) reported $3.2M in revenue over the twelve months to Jan 31, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
VitaNova's 2025 growth produced wider operating margins and positive cash flow, but reported earnings converted only partially into cash.
Cash conversion changed materially: FY2024's net income of$141K coincided with operating cash flow of-$376K . FY2025 reversed that mismatch, but operating cash flow of$193K was only22.7% of net income, indicating that earnings were recognized faster than collected.
Scale improved operating efficiency: revenue grew
The balance sheet is lightly burdened by liabilities: liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for VitaNova Life Sciences Corporation, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
VitaNova Life Sciences Corporation passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, VitaNova Life Sciences Corporation generates $0.23 in operating cash flow ($193K OCF vs $851K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
VitaNova Life Sciences Corporation earns $268.16 in operating income for every $1 of interest expense ($1.2M vs $5K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
VitaNova Life Sciences Corporation generated $710K in revenue in Q3 2026. This represents an increase of 130.2% from the same quarter a year earlier. Against the prior quarter it is up 66.1%.
VitaNova Life Sciences Corporation reported a net loss of $44K in Q3 2026. This represents a decrease of 160.8% from the same quarter a year earlier. Against the prior quarter it is down 223.9%.
VitaNova Life Sciences Corporation earned -$0.01 per diluted share (EPS) in Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
VitaNova Life Sciences Corporation held $1.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
VitaNova Life Sciences Corporation's gross margin was 44.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 16.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 16.5 percentage points.
VitaNova Life Sciences Corporation's operating margin was 6.6% in Q3 2026, reflecting core business profitability. This is down 28.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 16.6 percentage points.
VitaNova Life Sciences Corporation's net profit margin was -6.3% in Q3 2026, showing the share of revenue converted to profit. This is down 29.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.6 percentage points.
VitaNova Life Sciences Corporation's quarterly ROE was -2.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
Capital Allocation
None of these metrics is reported for Q3 2026.
YJGJD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'26Filing | Q1'26Filing | Q4'2510-Q | Q3'2510-Q | Q2'25Filing | Q1'25Filing | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $710K+130.2% | $427K+46.2% | $104K-4.2% | $2.0M | $308K+1081.3% | $292Kn/m | $108Kn/m | N/A |
| Cost of Revenue | $393K+230.5% | $166K+22.0% | $35K-0.5% | $796K | $119Kn/m | $136Kn/m | $35Kn/m | N/A |
| Gross Profit | $316K+67.1% | $261K+67.4% | $69K-6.0% | $1.2M | $189K+625.3% | $156Kn/m | $73Kn/m | N/A |
| SG&A Expenses | $220K+616.1% | $119K+197.8% | $66K+15.1% | $30K | $31K+52.2% | $40K+358.1% | $58K+137.4% | N/A |
| Operating Income | $47K-57.1% | $99K+58.4% | -$32Kn/m | $1.1M | $109K+1730.4% | $63Kn/m | -$45Kn/m | N/A |
| Interest Expense | $0-100.0% | $0-100.0% | N/A | N/A | $813n/m | $2Kn/m | N/A | N/A |
| Income Tax | $91K+158.2% | $63K+125.7% | $14K+41.5% | $280K | $35Kn/m | $28Kn/m | $10Kn/m | N/A |
| Net Income | -$44K-160.8% | $36K+9.7% | -$46Kn/m | $800K | $73K+1126.9% | $33Kn/m | -$55Kn/m | N/A |
| EPS (Basic) | -$0.01 | $0.00n/m | $0.00n/m | N/A | $0.01n/m | $0.00 | $0.00 | N/A |
| EPS (Diluted) | -$0.01 | $0.00n/m | $0.00n/m | N/A | $0.01n/m | $0.00 | $0.00 | N/A |
| Diluted Shares (Avg) | 8M | 25M0.0% | 25M0.0% | N/A | 8M+37.1% | 25M | 25M | N/A |
Not reported in any period shown, so not listed: R&D Expenses, EBITDA.
YJGJD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'26Filing | Q1'26Filing | Q4'2510-Q | Q3'2510-Q | Q2'25Filing | Q1'25Filing | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3M+75.0% | $2.3M+85.6% | $2.2M+86.7% | $2.3M+89.1% | $1.3M+37.0% | $1.3Mn/m | $1.2Mn/m | $1.2M+13567.0% |
| Current Assets | $2.3M+75.0% | $2.3M+85.6% | $2.2M+86.7% | $2.3M+89.1% | $1.3M+37.0% | $1.3Mn/m | $1.2Mn/m | $1.2M+13567.0% |
| Cash & Equivalents | $1.2M+188.5% | $1.3M+465.2% | $1.0M+639.0% | $783K+32.0% | $405K-49.9% | $223Kn/m | $142Kn/m | $593K+6694.6% |
| Inventory | $130K-30.1% | $11K-96.3% | $9K-95.7% | $44K-66.7% | $187K | $303K | $213K | $133Kn/m |
| Accounts Receivable | $1.0M+1759.5% | $883K+1429.7% | $1.0M | $1.3Mn/m | $54K | $58K | N/A | $0 |
| Total Liabilities | $458K+115.2% | $438K+95.6% | $380K+90.6% | $348K+153.8% | $213K+127.4% | $224K+142.8% | $199K+138.9% | $137K+101.5% |
| Current Liabilities | $458K+115.2% | $438K+95.6% | $380K+90.6% | $348K+153.8% | $213K+127.4% | $224K+142.8% | $199K+138.9% | $137K+101.5% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | $1.9M+67.3% | $1.9M+83.4% | $1.9M+86.0% | $1.9M+80.8% | $1.1M+27.3% | $1.0Mn/m | $1.0Mn/m | $1.1Mn/m |
| Retained Earnings | $813K+1106.6% | $857Kn/m | $821Kn/m | $868K+5017.7% | $67Kn/m | -$6Kn/m | -$38Kn/m | $17Kn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Long-Term Debt.
YJGJD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'26Filing | Q1'26Filing | Q4'2510-Q | Q3'2510-Q | Q2'25Filing | Q1'25Filing | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$90K-143.3% | $213K+2327.6% | $264Kn/m | $479Kn/m | $209Kn/m | $9Kn/m | -$504Kn/m | -$191Kn/m |
| Stock-Based Compensation | N/A | N/A | $0-100.0% | N/A | N/A | N/A | $750n/m | N/A |
| Financing Cash Flow | $0n/m | $0-100.0% | $0-100.0% | -$102Kn/m | -$27K-102.8% | $72K+806.0% | $53K+202.0% | -$24Kn/m |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
YJGJD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'26Filing | Q1'26Filing | Q4'2510-Q | Q3'2510-Q | Q2'25Filing | Q1'25Filing | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.6%-16.8pp | 61.1%+7.7pp | 66.2%-1.2pp | 59.3% | 61.4%-38.6pp | 53.3% | 67.5% | N/A |
| Operating Margin | 6.6%-28.7pp | 23.2%+1.8pp | -31.2%+10.7pp | 55.4% | 35.3%+12.5pp | 21.4% | -41.9% | N/A |
| Net Margin | -6.3%-29.9pp | 8.4%-2.8pp | -44.6%+6.3pp | 41.0% | 23.7%+0.9pp | 11.2% | -50.9% | N/A |
| Return on Equity | -2.4%-9.0pp | 1.9%-1.3pp | -2.5%+3.0pp | 41.9% | 6.6%+5.9pp | 3.1% | -5.5% | N/A |
| Return on Assets | -1.9%-7.4pp | 1.5%-1.1pp | -2.1%+2.5pp | 35.5% | 5.5%+4.9pp | 2.6% | -4.6% | N/A |
| Current Ratio | 5.05-1.2x | 5.33-0.3x | 5.90-0.1x | 6.49-2.2x | 6.21-4.1x | 5.62+5.6x | 6.02+6.0x | 8.71+8.6x |
| Liabilities-to-Equity | 0.25+0.1x | 0.230.0x | 0.200.0x | 0.18+0.1x | 0.19+0.1x | 0.22 | 0.20 | 0.13 |
| Asset Turnover | 0.31+0.1x | 0.180.0x | 0.050.0x | 0.87 | 0.23+0.2x | 0.23 | 0.09 | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Where VitaNova Life Sciences Corporation Ranks
Frequently Asked Questions
VitaNova Life Sciences Corporation (YJGJD) reported $2.7M in total revenue for fiscal year 2025. This represents a 366.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
VitaNova Life Sciences Corporation (YJGJD) revenue grew by 366.5% year-over-year, from $571K to $2.7M in fiscal year 2025.
Yes, VitaNova Life Sciences Corporation (YJGJD) reported a net income of $745K over the trailing 12 months to January 31, 2026. In fiscal year 2025 it reported a net income of $851K, with a net profit margin of 32.0%.
VitaNova Life Sciences Corporation (YJGJD) had a gross margin of 59.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
VitaNova Life Sciences Corporation (YJGJD) had an operating margin of 45.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
VitaNova Life Sciences Corporation (YJGJD) had a net profit margin of 32.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
VitaNova Life Sciences Corporation (YJGJD) has a return on equity of 45.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
VitaNova Life Sciences Corporation (YJGJD) generated $193K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
VitaNova Life Sciences Corporation (YJGJD) had $2.2M in total assets as of fiscal year 2025, including both current and long-term assets.
VitaNova Life Sciences Corporation (YJGJD) had a current ratio of 5.90 as of fiscal year 2025, which is generally considered healthy.
VitaNova Life Sciences Corporation (YJGJD) had a liabilities-to-equity ratio of 0.20 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
VitaNova Life Sciences Corporation (YJGJD) had a return on assets of 37.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
VitaNova Life Sciences Corporation (YJGJD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
VitaNova Life Sciences Corporation (YJGJD) has an earnings quality ratio of 0.23x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
VitaNova Life Sciences Corporation (YJGJD) has an interest coverage ratio of 268.16x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.